Vyome Therapeutics Receives Chinese Patent for Immuno-Inflammation Technology

The Chinese National Intellectual Property Administration has granted Vyome Therapeutics a new patent covering the company’s immuno-inflammation technology. This intellectual property protection expands the firm’s existing portfolio in the region and secures legal rights to its proprietary therapeutic developments within the Chinese market.

The patent specifically covers the company’s platform for addressing inflammatory conditions, providing Vyome with exclusive rights to its underlying technology for a set period. This development follows the company’s ongoing efforts to broaden its international patent footprint as it advances its clinical research. By securing this registration, Vyome establishes a legal framework to protect its research and development investments in China, which serves as a significant market for its immuno-inflammation pipeline.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: July 1, 2026

Author

GOAI